NCT01682876 - Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age. | Biotech Hunter

Enrollment

715

Participants

Timeline

Start Date

October 7, 2012

Primary Completion Date

July 2, 2013

Study Completion Date

May 30, 2014

Conditions

Meningococcal DiseaseInfections, Meningococcal

Interventions

BIOLOGICAL

MenACWY-CRM

The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm

Trial Locations (19)

13790

GSK Investigational Site, Johnson City

30062

GSK Investigational Site, Marietta

30189

GSK Investigational Site, Woodstock

32746

GSK Investigational Site, Lake Mary

35205

GSK Investigational Site, Birmingham

40291

GSK Investigational Site, Louisville

44121

GSK Investigational Site, Cleveland

44122

GSK Investigational Site, Cleveland

49120

GSK Investigational Site, Niles

49127

GSK Investigational Site, Stevensville

51503

GSK Investigational Site, Council Bluffs

68005

GSK Investigational Site, Bellevue

68025

GSK Investigational Site, Fremont

68134

GSK Investigational Site, Omaha

70006

GSK Investigational Site, Metairie

76135

GSK Investigational Site, Fort Worth

78705

GSK Investigational Site, Austin

84088

GSK Investigational Site, West Jordan

95822

GSK Investigational Site, Sacramento